Kalamazoo, Michigan, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced today that after 15 years of distinguished service, Dr. Srikant Datar has notified the Company that he will not stand for re-election at Stryker's 2024 Annual Meeting of Shareholders, which is expected to be held on May 9, 2024.
Dr. Datar is the Dean of the Harvard Business School and George F. Baker Professor of Business Administration. He was the Arthur Lowes Dickinson Professor at the Graduate School of Business Administration of Harvard University from 1996 to 2020 and is the former Faculty Chair of the Harvard Innovation Labs and Senior Associate Dean for University Affairs. From 1989 to 1996, Dr. Datar was Edmund W. Littlefield Professor at the Graduate School of Business, Stanford University. Dr. Datar is also a director of ICF International, Inc., a management, technology and policy consulting firm, and T-Mobile US, Inc., a provider of wireless voice, messaging and data services. In 2020, he was recognized by the National Association of Corporate Directors (NACD) as Public Company Director of the Year.
Dr. Datar has an extensive background in accounting and finance and a variety of other business areas, including performance measurement, design thinking and innovation, and machine learning and artificial intelligence. His strong academic and business background and board experience for high tech global companies has helped us accelerate our global growth through focus on organic and M&A innovation.
“We sincerely appreciate Srikant’s many contributions to the Board over the years and thank him for being a strategic resource and champion of our growth ambitions,” said Kevin Lobo, Chair and Chief Executive Officer. “We wish Srikant all the best and thank him for his guidance in helping Stryker deliver on its mission of making healthcare better.”
Stryker is one of the world’s leading medical technology companies and, together with its customers, is driven to make healthcare better. The company offers innovative products and services in Medical and Surgical, Neurotechnology, Orthopaedics and Spine that help improve patient and healthcare outcomes. Alongside its customers around the world, Stryker impacts more than 130 million patients annually. More information is available at www.stryker.com.
Contacts
For investor inquiries please contact:
Jason Beach, Vice President, Investor Relations at 269-385-2600 or This email address is being protected from spambots. You need JavaScript enabled to view it.
For media inquiries please contact:
Yin Becker, Vice President, Chief Corporate Affairs Officer at 269-385-2600 or This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$364.60 |
Daily Change: | 7.46 2.09 |
Daily Volume: | 2,828,489 |
Market Cap: | US$138.990B |
November 19, 2024 November 14, 2024 October 29, 2024 September 20, 2024 September 17, 2024 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORETerns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB